Teijin (3401) Q3 2026 earnings summary

Executive summary

• Revenue for Q3/FY2025 declined by JPY 96.2 billion year-on-year to JPY 659.9 billion, mainly due to business divestments and weak materials segment performance.

• Adjusted operating income for Q3 was JPY 23.8 billion, down JPY 1.8 billion year-on-year, impacted by declines in materials and the exclusion of aramid paper business profits.

• Net loss attributable to owners for Q3/nine months was JPY 59 billion, primarily due to impairment losses and structural reforms in aramid and carbon fibers businesses.

• Healthcare segment income increased, offsetting declines in Materials and Fibers & Products Converting segments.

• Significant impairment losses and divestitures, including the sale of North American composites and Teijin Nakashima Medical, impacted results.

Financial highlights

• Revenue for Q3/FY2025: JPY 659.9 billion, down JPY 96.2 billion year-on-year.

• Adjusted operating income: JPY 23.8 billion, down JPY 1.8 billion year-on-year.

• Net loss attributable to owners: JPY 59 billion for Q3/nine months.

• EBITDA: JPY 70.0 billion, down JPY 9.7 billion year-on-year.

• Operating cash flow improved to JPY 73.2 billion, up JPY 32.3 billion year-on-year.

Outlook and guidance

• Full-year/FY2025 revenue forecast: JPY 860 billion, a 14.5% decrease year-on-year.

• Adjusted operating income forecast: JPY 25 billion.

• Net loss forecast: JPY 10 billion, with annual dividend forecast unchanged at JPY 50 per share.

• Revenue and income outlooks unchanged despite business divestments and impairment losses.